ANEB Logo

Anebulo Pharmaceuticals, Inc. (ANEB) 

NASDAQ
Market Cap
$41.1M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
434 of 776
Rank in Industry
228 of 433

Largest Insider Buys in Sector

ANEB Stock Price History Chart

ANEB Stock Performance

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Insider Activity of Anebulo Pharmaceuticals, Inc.

Over the last 12 months, insiders at Anebulo Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Anebulo Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Anebulo Pharmaceuticals, Inc. have bought $105,079 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 400 shares for transaction amount of $2,634 was made by English Aron R. () on 2021‑12‑17.

List of Insider Buy and Sell Transactions, Anebulo Pharmaceuticals, Inc.

2021-12-17Purchase
400
0.0016%
$6.59$2,634-43.79%
2021-12-14Purchase
412
0.0015%
$5.89$2,429-40.48%
2021-12-03Purchase
4,500
0.0153%
$5.93$26,685-42.67%
2021-12-02Purchase
13,836
0.0441%
$5.30$73,331-39.35%

Insider Historical Profitability

<0.0001%
English Aron R.
3362713
12.9668%
$1.5940<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.